Intrexon bets $26M on stem cells, teams up with troubled OvaScience

Intrexon ($XON), a Maryland biotech backed by billionaire RJ Kirk, has agreed to snap up a San Diego regenerative medicine outfit for $26 million, and the company inked a separate agreement with OvaScience ($OVAS) to combine their technology platforms. In its buyout of Medistem, Intrexon will acquire blood vessel-forming stem cell technology with applications in cancer, wound healing, and cardiovascular disease, the company said, fueling some early-stage development projects. With OvaScience, a biotech still recovering from some FDA scorn, Intrexon is launching a joint venture called OvaXon that unites the duo's development platforms for human and animal fertility treatments. Medistem | OvaScience

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.